Innoviva Résultats passés

Passé contrôle des critères 2/6

Innoviva's earnings have been declining at an average annual rate of -12%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 2.6% per year. Innoviva's return on equity is 21.9%, and it has net margins of 44%.

Informations clés

-12.0%

Taux de croissance des bénéfices

-0.6%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie	6.0%
Taux de croissance des recettes	2.6%
Rendement des fonds propres	21.9%
Marge nette	44.0%
Dernière mise à jour des bénéfices	30 Jun 2024

Mises à jour récentes des performances passées

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Recent updates

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

Ventilation des recettes et des dépenses

Comment Innoviva gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

NasdaqGS:INVA Recettes, dépenses et bénéfices (USD Millions )
Date	Recettes	Les revenus	Dépenses G+A
30 Jun 24	330	145	113
31 Mar 24	312	181	109
31 Dec 23	310	180	98
30 Sep 23	290	50	84
30 Jun 23	290	233	83
31 Mar 23	318	233	71
31 Dec 22	331	214	58
30 Sep 22	373	293	46
30 Jun 22	404	99	21
31 Mar 22	396	188	13
31 Dec 21	392	266	16
30 Sep 21	375	309	17
30 Jun 21	365	265	17
31 Mar 21	344	253	16
31 Dec 20	337	224	12
30 Sep 20	322	216	8
30 Jun 20	299	228	9
31 Mar 20	285	189	11
31 Dec 19	261	157	15
30 Sep 19	265	375	17
30 Jun 19	261	382	13
31 Mar 19	264	399	13
31 Dec 18	261	395	19
30 Sep 18	251	190	17
30 Jun 18	238	166	24
31 Mar 18	229	147	30
31 Dec 17	217	134	32
30 Sep 17	191	101	35
30 Jun 17	176	92	32
31 Mar 17	150	72	28
31 Dec 16	134	60	23
30 Sep 16	113	38	22
30 Jun 16	93	19	22
31 Mar 16	71	-4	21
31 Dec 15	54	-19	20
30 Sep 15	38	-39	21
30 Jun 15	26	-56	25
31 Mar 15	16	-68	29
31 Dec 14	8	-74	35
30 Sep 14	3	-66	35
30 Jun 14	2	-55	32
31 Mar 14	2	-9	27
31 Dec 13	5	-31	24

Des revenus de qualité: INVA has high quality earnings.

Augmentation de la marge bénéficiaire: INVA's current net profit margins (44%) are lower than last year (80.3%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: INVA's earnings have declined by 12% per year over the past 5 years.

Accélération de la croissance: INVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: INVA had negative earnings growth (-37.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.4%).

Innoviva Résultats passés

Passé contrôle des critères 2/6

Informations clés

Mises à jour récentes des performances passées

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Recent updates

Price target increased by 20% to US$18.00

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Innoviva: Potentially Overvalued

Now 21% undervalued

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Price target decreased by 23% to US$13.00

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 12% to US$15.17

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva Stock? Not Yet. Short Puts? Definitely.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Price target decreased to US$18.67

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Price target increased to US$20.50

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Innoviva Inc.: Short Puts Are Compelling

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Independent Chairman of the Board recently bought US$264k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva reports Q1 results

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

New 90-day high: US$12.51

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Investor sentiment improved over the past week

New 90-day high: US$11.81

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Innoviva: Only For Short-Term Traders